Ongoing work in our laboratory seeks to identify the optimal biopharmaceutical delivery route and form (protein, gene therapy, agonist antibody or small synthetic molecule) for neurotrophin-3 and for targeting its receptors after spinal cord injury and stroke. Here, NTF3 is linked to stroke disorder.